NBIX · Insider Trading
Neurocrine Biosciences Inc
Every open-market purchase and sale reported by NBIX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-05 | Eiry Roberts | Chief Medical Officer | A | +9,820 deriv. | — |
| 2026-11-03 | Kyle Gano | Chief Executive Officer | MIXED | +282 | −$48.51K |
| 2026-11-03 | George J Morrow | Director | MIXED | — | −$1.53M |
| 2026-09-15 | Matt Abernethy | Chief Financial Officer | MIXED | — | −$786.48K |
| 2026-09-15 | Darin Lippoldt | Chief Legal Officer | MIXED | +2,064 | −$377.90K |
| 2026-09-15 | David W. Boyer | Chief Corp. Affairs Officer | MIXED | +825 | −$432.49K |
| 2026-09-15 | Kevin Charles Gorman | Director | MIXED | +6,504 | −$1.22M |
| 2026-09-15 | Sanjay Chandru Keswani | Chief Medical Officer | MIXED | +1,802 | −$329.94K |
| 2026-09-15 | Julie Cooke | Chief Human Resources Officer | MIXED | +1,651 | −$302.44K |
| 2026-09-15 | Eric Benevich | Chief Commercial Officer | MIXED | +2,889 | −$528.96K |
| 2026-09-15 | Ingrid Delaet | Chief Regulatory Officer | MIXED | +2,064 | −$377.90K |
| 2026-09-15 | Kyle Gano | Chief Executive Officer | MIXED | +3,737 | −$684.24K |
| 2026-09-15 | Jude Onyia | Chief Scientific Officer | MIXED | +1,651 | −$302.44K |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | MIXED | +1,040 | −$194.92K |
| 2026-09-03 | Stephen A Sherwin | Director | G | −1,000 | — |
| 2026-08-05 | Jude Onyia | Chief Scientific Officer | G | −2,409 | — |
| 2026-07-30 | Leslie V Norwalk | Director | MIXED | −408 | −$110.11K |
| 2026-07-13 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | −$327.53K |
| 2026-07-13 | Darin Lippoldt | Chief Legal Officer | MIXED | — | −$981.11K |
| 2026-07-09 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | −$1.09M |
| 2026-06-09 | Jude Onyia | Chief Scientific Officer | G | −2,441 | — |
| 2026-06-09 | Stephen A Sherwin | Director | MIXED | — | −$2.53M |
| 2026-06-08 | Leslie V Norwalk | Director | Sell | −1,250 | −$210.07K |
| 2026-06-04 | Sanjay Chandru Keswani | Chief Medical Officer | MIXED | +1,479 | −$268.34K |
| 2026-06-04 | Julie Cooke | Chief Human Resources Officer | MIXED | −11,972 | −$3.74M |
| 2026-06-02 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | −$175.66K |
| 2026-06-02 | Jude Onyia | Chief Scientific Officer | MIXED | — | −$830.57K |
| 2026-05-29 | Leslie V Norwalk | Director | A | +3,908 deriv. | — |
| 2026-05-29 | William H Rastetter | Director | A | +2,567 deriv. | — |
| 2026-05-29 | George J Morrow | Director | A | +2,567 deriv. | — |
| 2026-05-29 | Stephen A Sherwin | Director | A | +2,567 deriv. | — |
| 2026-05-29 | Shalini Sharp | Director | A | +2,567 deriv. | — |
| 2026-05-29 | Christine A Poon | Director | A | +2,567 deriv. | — |
| 2026-05-29 | Johanna Mercier | Director | A | +2,567 deriv. | — |
| 2026-05-29 | Gary A Lyons | Director | A | +3,908 deriv. | — |
| 2026-05-29 | Richard F Pops | Director | A | +2,567 deriv. | — |
| 2026-05-29 | Kevin Charles Gorman | Director | A | +5,248 deriv. | — |
| 2026-05-29 | Jude Onyia | Chief Scientific Officer | MIXED | — | −$778.73K |
| 2026-05-28 | David W. Boyer | Chief Corp. Affairs Officer | Sell | −3,888 | −$609.02K |
| 2026-05-21 | Kevin Charles Gorman | Director | MIXED | −40,000 | −$28.96M |
| 2026-05-21 | Gary A Lyons | Director | M | +1,659 | — |
| 2026-05-21 | Johanna Mercier | Director | M | +3,318 | — |
| 2026-05-21 | George J Morrow | Director | M | +3,318 | — |
| 2026-05-21 | Leslie V Norwalk | Director | M | +1,659 | — |
| 2026-05-21 | Christine A Poon | Director | M | +3,318 | — |
| 2026-05-21 | Richard F Pops | Director | M | +3,318 | — |
| 2026-05-21 | William H Rastetter | Director | M | +3,318 | — |
| 2026-05-21 | Shalini Sharp | Director | M | +1,659 | — |
| 2026-05-21 | Stephen A Sherwin | Director | M | +3,318 | — |
| 2026-05-18 | Richard F Pops | Director | MIXED | — | −$1.65M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kevin Charles Gorman | Director | 517,797 | $87.20M |
| Kyle Gano | Chief Executive Officer | 155,010 | $26.11M |
| Gary A Lyons | Director | 122,141 | $20.57M |
| Eric Benevich | Chief Commercial Officer | 70,683 | $11.90M |
| Darin Lippoldt | Chief Legal Officer | 59,212 | $9.97M |
| Matt Abernethy | Chief Financial Officer | 47,828 | $8.05M |
| William H Rastetter | Director | 43,678 | $7.36M |
| Richard F Pops | Director | 37,798 | $6.37M |
| Eiry Roberts | Chief Medical Officer | 34,252 | $5.77M |
| Julie Cooke | Chief Human Resources Officer | 24,025 | $4.05M |
| Jude Onyia | Chief Scientific Officer | 22,647 | $3.81M |
| Ingrid Delaet | Chief Regulatory Officer | 18,289 | $3.08M |
| Stephen A Sherwin | Director | 14,860 | $2.50M |
| George J Morrow | Director | 13,186 | $2.22M |
| David W. Boyer | Chief Corp. Affairs Officer | 11,484 | $1.93M |
| Johanna Mercier | Director | 6,853 | $1.15M |
| Christine A Poon | Director | 4,753 | $800.45K |
| Shalini Sharp | Director | 4,088 | $688.46K |
| Sanjay Chandru Keswani | Chief Medical Officer | 3,281 | $552.55K |
| Leslie V Norwalk | Director | 2,430 | $409.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NBIX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.